StockData
UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31

Upstream Bio, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$2.80+0.04 (+1.45%)

Close on Oct 19, 2026

Market cap
$152.79M
P/E (TTM)
–
Dividend yield
–

SEC filings

26 of Upstream Bio's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report8-KSep 1, 2026Sep 1, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 11, 2026SEC EDGAR
Current report8-KAug 11, 2026Aug 11, 2026SEC EDGAR
Current report8-KJun 9, 2026Jun 10, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 13, 2026SEC EDGAR
Current report8-KMay 13, 2026May 13, 2026SEC EDGAR
Proxy statementDEF 14AJun 9, 2026Apr 16, 2026SEC EDGAR
Current report8-KMar 26, 2026Mar 26, 2026SEC EDGAR
Annual report10-KDec 31, 2025Mar 26, 2026SEC EDGAR
Current report8-KMar 26, 2026Mar 26, 2026SEC EDGAR
Current report8-KFeb 11, 2026Feb 11, 2026SEC EDGAR
Current report8-KFeb 11, 2026Feb 11, 2026SEC EDGAR
Quarterly report10-QSep 30, 2025Nov 5, 2025SEC EDGAR
Current report8-KNov 5, 2025Nov 5, 2025SEC EDGAR
Current report8-KSep 2, 2025Sep 2, 2025SEC EDGAR
Quarterly report10-QJun 30, 2025Aug 6, 2025SEC EDGAR
Current report8-KAug 6, 2025Aug 6, 2025SEC EDGAR
Current report8-KJun 10, 2025Jun 12, 2025SEC EDGAR
Quarterly report10-QMar 31, 2025May 6, 2025SEC EDGAR
Current report8-KMay 6, 2025May 6, 2025SEC EDGAR
Proxy statementDEF 14AJun 10, 2025Apr 17, 2025SEC EDGAR
Annual report10-KDec 31, 2024Mar 12, 2025SEC EDGAR
Current report8-KMar 12, 2025Mar 12, 2025SEC EDGAR
Quarterly report10-QSep 30, 2024Nov 7, 2024SEC EDGAR
Current report8-KNov 7, 2024Nov 7, 2024SEC EDGAR
Current report8-KOct 10, 2024Oct 15, 2024SEC EDGAR